Febuxostat API
Appearance: White to off-white crystalline powder
Standard: in-house
Supply Ability:2000kg per month
Shelf Life: Two years
Payment: T/T, LC or DA
Delivery Time: Ready Stock in Local Warehouse, 1-3 days
Origin: China
Shipping: DHL, FedEx, TNT, EMS, By Sea, By Air
Can't sell to individuals
- Fast Delievery
- Quality Assurance
- 24/7 Customer Service
Product Introduction
We supply Febuxostat API
We give high- quality Febuxostat API, which is a potent xanthine oxidase asset generally used in the treatment of hyperuricemia and gout. Our product is produced in compliance with strict quality control norms, icing its effectiveness and chastity. also, we offer competitive pricing and timely delivery to our guests. Trust us to meet your Febuxostat conditions with our top- notch product and excellent client service. communicate us moment to learn further about our immolation and how we can help you in your medicinal manufacturing requirements.
What's Febuxostat ?
The chemical name of febuxostat is 2-(( 3- cyano-4-isobutyloxy) phenyl)-4-methyl-5-thiazolium carboxylic acid. As an asset of xanthine oxidase( XO), it's suitable for long- term treatment of hyperuricemia with gout symptoms.
it is a new generation of xanthine oxidase asset developed by Teijin Corporation in Japan. It's clinically used to treat hyperuricemia( gout) and has a fully different structure from the xanthine oxidase asset medicine developed 40 times agone
. It's a new and effective non purine xanthine oxidase picky asset. Xanthine oxidase is a crucial enzyme that promotes uric acid product. it can reduce the situations of Chemicalbook uric acid in the blood of gout cases with hyperuricemia. Clinical studies have shown that this product is safe and effective. It's metabolized by the liver and doesn't calculate on renal excretion. thus, it isn't necessary to reduce the lozenge for cases with moderate to severe liver and order dysfunction. The lozenge is formerly daily, 40 mg or 80 mg, and isn't recommended for treating gout cases without hyperuricemia. In February 2009, the US Food and Drug Administration( FDA) approved it for long- term treatment of gout and hyperuricemia cases.
Basic Information
Product Name: Febuxostat
CAS: 144060-53-7
MF:C16H16N2O3S
MW:316.37
EINECS:682-158-6
MDL No.:MFCD00871598
Structural formula:
Origin: China
Application: Anti gout medication for gout patients with hyperuricemia
Delivery Time: in stock
Technical Specification
Items |
Specifications |
Results |
Appearance |
White to off-white crystalline powder |
Off-white crystalline powder |
Identification |
A: UV B: HPLC |
Conforms Conforms |
Related substances (by HPLC) |
Individual impurity: NMT 0.1% Total impurities: NMT 0.5% |
0.08% 0.09% |
Residual solvents |
Methanol: NMT 0.3% Ethanol: NMT 0.5% Formic acid: NMT 0.5% DMF: NMT 0.088% |
ND ND ND ND |
Loss on drying |
NMT 1.0% |
0.38% |
Residue on ignition |
NMT 0.1% |
0.06% |
Heavy metals |
NMT 20ppm |
Conforms |
Chlorides |
NMT 0.04% |
Conforms |
Assay |
NLT 98.5% |
99.80% |
Conclusion: the product conforms to the above specifications. |
Package: 1kg; 25kg
Storage: 2-8℃.Store in tight, light- resistant holders, avoid exposure to direct sun, humidity and inordinate heat.
Shelf Life 24 months
Antigout drugs
Gout is a miscellaneous complaint caused by inheritable or acquired factors similar as dropped uric acid excretion and purine metabolism diseases. Due to inordinate product of uric acid in the body and dropped renal concurrence capability, uric acid accumulates in the body, leading to the deposit of urate chargers in joints and colorful organs. thus, the treatment of gout generally involves promoting uric acid excretion and inhibiting uric acid product, and taking applicable measures to ameliorate affiliated symptoms. The generation of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine is generated by the action of xanthine oxidoreductase( XOR) to produce xanthine, which further generates uric acid. Inhibiting the exertion of this enzyme can effectively reduce the generation of uric acid. It is the rearmost developed next- generation non purine picky xanthine oxidase asset in the world. It acts largely widely on the oxidase, reducing uric acid conflation in the body and lowering uric acid attention, therefore effectively treating ventilation conditions. For 30 times, allopurinol has been the only medicine clinically used to inhibit uric acid product and has been extensively used as a gold treatment for gout, achieving remarkable results in the treatment of gout. Compared to allopurine, febuxostat API has significant advantages
( 1) Allopurinol only has an inhibitory effect on reduced XOR, while It has a significant inhibitory effect on both oxidative and reduced XOR, making its uric acid lowering effect more important and long- continuing;
( 2) Due to the fact that allopurinol is a purine analogue, it inescapably affects the exertion of other enzymes involved in purine and pyridine metabolism. thus, in the treatment of allopurinol, repeated high- cure administration is necessary to maintain high medicine situations. This also brings serious or indeed fatal adverse responses caused by medicine accumulation. Andnon-buxostat is a non purine XOR asset, thus it has better safety.
Drugs that increase the risk of gout
Diuretics furosemide, hydrochlorothiazide, metolazone
Salicylic acids similar as aspirin and niacin
Cyclosporine Neoral
Levodopa
Intermediate
4- hydroxythiobenzamide CASNo. 25984-63-8 Appearance Light green to out white powder.
2-( 4- hydroxyphenyl)-4-methylthiazole-5-ethyl formate CAS Chemicalbook161797-99-5 Appearance unheroic powder.
2-( 3- Aldehyde-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester CASNo. 161798-01-2 Appearance Light unheroic to unheroic powder.
2-( 3- Aldehyde-4-Isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester CASNo. 161798-03-4 Appearance Light unheroic to out white powder.
2-( 3- Cyano-4-Isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester CASNo. 160844-75-7 Appearance Off white to white powder.
Clinical application
Febuxostat is generally restated as febuxostat in clinical practice. It's a drug that reduces uric acid product and should be taken under medical advice. This medicine can reduce uric acid conflation in the body and is a generally used drug for treating gout, which can ameliorate the symptoms of gout in cases. When cases take it, they should follow the croaker's advice and not increase or drop the lozenge arbitrarily to avoid poor treatment effect.
purpose
Treating hyperuricemia( gout)
A xanthine oxidase and xanthine dehydrogenase asset.
Payment Term
Why Choose Xi'an Yihui?
Customer feedback
Xi'an Yihui certificates
Xi'an Yihui Factory & Warehouse
Our Advantage
Rich experience: we have 13 Years of professional experience;
Customers all over the world: sell to more than 100 countries;
Provide diversified products: the products have been applied to all major international brands in the fields of drugs, dietary supplements, cosmetics, animal nutrition and functional food.
Price advance: low MOQ with competitive price;
Quality certification: ISO; Halal; Kosher certified
After-sales service: Professional team 7*24 hours customer service.
In conclusion
In summary, as a professional Febuxostat API manufacturer, we have advanced technology, scale advantage, the best quality, rich production experience, and excellent services. These advantages will make it stand out in the market competition and win more customer trust and support. if you need it, pls feel free to contact us any time. we will reply you asap.
our contact information:
E-mail: sales@yihuipharm.com
Tel: 0086-29-89695240
WeChat or WhatsApp: 0086-17792415937
Send Message
If you have any enquiry about quotation or cooperation, please feel free to email us at E-mailor use the following enquiry form. Our sales representative will contact you within 24 hours.Thank you for your interest in our products.